mismatch repair deficiency
Roche Nabs FDA Label Expansion for Ventana CDx Panel
The immunohistochemistry companion diagnostic helps identify patients with solid tumors that are deficient in DNA mismatch repair.
In new guidelines, an expert panel recommended IHC and PCR for certain cancer types and pointed out knowledge gaps supporting NGS in other settings.
Rectal Cancer Patient Subset Shows Complete Response to Immunotherapy in Small Study
First-line treatment with the anti-PD-1 drug Jemperli prompted a clinical complete response in 12 early-stage rectal carcinoma patients, who have been able to avoid further treatment so far.
Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors
European regulators approved the agent for PD-L1-positive cervical cancer and for five tumor types defined by high microsatellite instability or DNA mismatch repair deficiency.
MSK Researchers Testing if Chemo-Induced Hypermutated Colon Cancers Respond to BMS'Â OpdivoÂ
Based on encouraging data in mice, investigators are assessing if temozolomide-cisplatin can make patients'Â "cold" tumors respond to checkpoint blockade.Â